Biodelivery Sciences International (BDSI) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 12, 2013
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'BIODELIVERY SCIENCES INTERNATIONAL INC	'
Entity Central Index Key	'0001103021	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	38,040,518

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$38,296,062	$63,189,307
Accounts receivable, other	885,448	520,812
Prepaid expenses and other current assets	454,675	226,064
Total current assets	39,636,185	63,936,183
Equipment, net	174,524	2,835,707
Idle equipment, net (note 1)	2,469,178	'
Goodwill	2,715,000	2,715,000
Other intangible assets:	'	'
Licenses	1,900,000	1,900,000
Acquired product rights	9,050,000	9,050,000
Accumulated amortization	-5,510,913	-4,770,516
Total other intangible assets	5,439,087	6,179,484
Derivative asset, warrant (note 1)	'	50,300
Other assets	131,860	21,976
Total assets	50,565,834	75,738,650
Current liabilities:	'	'
Accounts payable and accrued liabilities	11,070,312	10,755,049
Notes payable, current	5,333,333	'
Deferred revenue, current	4,074,844	7,990,231
Derivative liabilities (note 1)	3,948,006	4,497,977
Total current liabilities	24,426,495	23,243,257
Note payable, less current maturities	13,762,511	'
Deferred revenue, long-term	1,330,051	2,718,180
Total liabilities	39,519,057	25,961,437
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred Stock, $.001 par value; 5,000,000 shares authorized; 2,709,300 shares of Series A Non-Voting Convertible Preferred Stock outstanding in 2013 and 2012	2,709	2,709
Common Stock, $.001 par value; 75,000,000 shares authorized; 38,181,544 and 37,497,703 shares issued; 38,166,053 and 37,482,212 shares outstanding in 2013 and 2012, respectively	38,182	37,499
Additional paid-in capital	149,596,562	143,703,583
Treasury stock, at cost, 15,491 shares, 2013 and 2012	-47,183	-47,183
Accumulated deficit	-138,543,493	-93,919,395
Total stockholders' equity	11,046,777	49,777,213
Total liabilities and stockholders' equity	$50,565,834	$75,738,650

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012
			Series A Non-Voting Convertible Preferred Stock [Member]	Series A Non-Voting Convertible Preferred Stock [Member]
Preferred Stock, par value	$0.00	$0.00	'	'
Preferred Stock, shares authorized	5,000,000	5,000,000	'	'
Preferred Stock, shares outstanding	'	'	2,709,300	2,709,300
Common Stock, par value	$0.00	$0.00	'	'
Common Stock, shares authorized	75,000,000	75,000,000	'	'
Common Stock, shares issued	38,181,544	37,497,703	'	'
Common Stock, shares outstanding	38,166,053	37,482,212	'	'
Treasury Stock, shares	15,491	15,491	'	'

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:	'	'	'	'
Product royalties	$924,272	'	$1,779,373	'
Research revenues	'	'	'	13,375
Contract revenues	2,072,590	1,875,446	5,603,516	34,677,583
Total Revenues:	2,996,862	1,875,446	7,382,889	34,690,958
Cost of product royalties	643,486	375,000	1,708,693	1,125,000
Expenses:	'	'	'	'
Research and development	16,387,194	12,546,912	41,177,577	23,804,276
General and administrative	3,039,255	2,992,354	9,060,265	8,042,433
Related party general and administrative, net	9,750	20,000	39,250	65,750
Total Expenses:	19,436,199	15,559,266	50,277,092	31,912,459
(Loss) income from operations	-17,082,823	-14,058,820	-44,602,896	1,653,499
Interest (expense) income, net	-450,328	90,167	-281,812	210,284
Derivative (loss) gain	-917,863	-3,525,011	499,671	-8,871,050
Other (expense) income, net	-35,433	16,377	-154,061	63,237
Loss before taxes	-18,486,447	-17,477,287	-44,539,098	-6,944,030
Income tax expense	'	'	-85,000	'
Net loss attributable to common stockholders	($18,486,447)	($17,477,287)	($44,624,098)	($6,944,030)
Basic and diluted earnings per share	($0.49)	($0.58)	($1.18)	($0.23)
Weighted average common stock shares outstanding	38,076,606	30,071,813	37,864,248	29,768,620

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Stockholders Equity (USD $)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Series A Preferred Stock [Member]
Beginning Balance at Dec. 31, 2012	$49,777,213	$37,499	$143,703,583	($47,183)	($93,919,395)	$2,709
Beginning Balance, Shares at Dec. 31, 2012	'	37,497,703	'	'	'	2,709,300
Stock-based compensation	2,487,730	'	2,487,730	'	'	'
Restricted stock awards	'	80	-80	'	'	'
Restricted stock awards, Shares	'	80,498	'	'	'	'
Shares issued to Arcion in acquisition of research and development license	2,072,136	500	2,071,636	'	'	'
Shares issued to Arcion in acquisition of research and development license, Shares	'	500,516	'	'	'	'
Exercise of stock options	347,434	103	347,331	'	'	'
Exercise of stock options, Shares	102,827	102,827	'	'	'	'
Warrants issued to MidCap	986,362	'	986,362	'	'	'
Net loss	-44,624,098	'	'	'	-44,624,098	'
Ending Balance at Sep. 30, 2013	$11,046,777	$38,182	$149,596,562	($47,183)	($138,543,493)	$2,709
Ending Balance, Shares at Sep. 30, 2013	'	38,181,544	'	'	'	2,709,300

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Operating activities:	'	'
Net loss	($44,624,098)	($6,944,030)
Adjustments to reconcile net loss to net cash flows from operating activities:	'	'
Depreciation and amortization	956,008	1,120,741
Accretion of discount	82,198	'
Derivative (gain) loss	-499,671	8,871,050
Purchase of Arcion license with common stock	2,072,136	'
Stock-based compensation expense	2,487,730	1,088,769
Issuance of common stock	'	285,201
Changes in assets and liabilities:	'	'
Accounts receivable	-364,636	76,829
Prepaid expenses and other assets	-131,660	2,398
Accounts payable and accrued expenses	299,974	2,327,264
Income tax payable	85,000	'
Deferred revenue	-5,303,516	12,822,417
Net cash flows (used in) provided by operating activities	-44,940,535	19,650,639
Investing activities:	'	'
Purchase of equipment	-5,521	-32,283
Purchase of intangible assets	'	-1,050,000
Net cash flows from investing activities	-5,521	-1,082,283
Financing activities:	'	'
Proceeds from exercise of stock options	347,434	1,873,397
Proceeds from exercise of warrants	'	135,000
Proceeds from notes payable and warrants	20,000,000	'
Deferred financing fees	-224,917	'
Change in amounts due to related parties	-69,706	-7,805
Net cash flows from financing activities	20,052,811	2,000,592
Net change in cash and cash equivalents	-24,893,245	20,568,948
Cash and cash equivalents at beginning of period	63,189,307	10,750,205
Cash and cash equivalents at end of period	$38,296,062	$31,319,153

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	1	Basis of presentation:
	Overview:
	The accompanying unaudited condensed consolidated financial statements of BioDelivery Sciences International, Inc., a Delaware corporation, together with its wholly-owned subsidiaries, Arius Pharmaceuticals, Inc., a Delaware corporation (“Arius One”), and Arius Two, Inc., a Delaware corporation (“Arius Two”), and its majority-owned, inactive subsidiary, Bioral Nutrient Delivery, LLC, a Delaware limited liability company (“BND”, together with Arius One and Arius Two, collectively, the “Company” or “we”, “us” or similar terminology) have been prepared by the Company without audit. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2013, and for all periods presented, have been made. All intercompany accounts and transactions have been eliminated.
	Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the Securities and Exchange Commission (“SEC”) rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2012, which are included in the Company’s 2012 Annual Report on Form 10-K, filed with the SEC on March 18, 2013 (the “2012 Annual Report”). The accompanying condensed consolidated balance sheet at December 31, 2012 has been derived from the audited financial statements at that date, but does not include all information and notes required by GAAP for complete financial statements.
	The Company is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. The Company is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction.
	The Company’s pain franchise currently consists of four products, three of which utilize the patented BioErodible MucoAdhesive (“BEMA”) drug delivery technology, a thin film applied to the inner lining of the cheek. ONSOLIS® (fentanyl buccal soluble film) is approved in the U.S., Canada, E.U. (where it is marketed as BREAKYL) and Taiwan (where it is marketed as PAINKYL™), for the management of breakthrough pain in opioid tolerant, adult patients with cancer. The commercial rights to ONSOLIS® are licensed to Meda AB (“Meda”) for all territories worldwide except for Taiwan (licensed to TTY Biopharm Co. Ltd. (“TTY”)) and South Korea (licensed to Kunwha Pharmaceutical Co., Ltd. (“Kunwha”)). The Company’s second pain product using the BEMA® technology, BEMA® Buprenorphine, is in Phase 3 clinical trials for the treatment of moderate to severe chronic pain and is licensed on a worldwide basis to Endo Health Solutions, Inc. (“Endo”). Additionally, in October 2013, the U.S. Food and Drug Administration (“FDA”) accepted the Company’s New Drug Application for BUNAVAIL™ (buprenorphine naloxone buccal film), a high dose formulation of buprenorphine in combination with naloxone for the maintenance treatment of opioid dependence. FDA’s decision on the BUNAVAIL™ New Drug Application (“NDA”) is due in June 2014. The Company’s fourth pain product in development is Clonidine Topical Gel for the treatment of painful diabetic neuropathy, which was licensed from Arcion Therapeutics, Inc. (“Arcion”) in March 2013.
	The results of operations for the nine month period ended September 30, 2013 are not necessarily indicative of results that may be expected for any other interim period or for the full fiscal year. Readers of this Quarterly Report are strongly encouraged to review the risk factors relating to the Company which are set forth in the 2012 Annual Report.
	BDSI® and BEMA® are registered trademarks of the Company. The BioDelivery Sciences logo and BUNAVAILTM are trademarks owned by the Company. ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc. BREAKYL™ is a trademark owned by Meda Pharma GmbH & Co. KG. PAINKYL™ is a trademark owned by TTY Biopharm. All other trademarks and tradenames are owned by their respective owners.
	As used herein, the term “Common Stock” means the Company’s common stock, par value $.001 per share.
	Fair value of financial assets and liabilities:
	The Company measures the fair value of financial assets and liabilities in accordance with GAAP which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.
	GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:
	Level 1 – quoted prices in active markets for identical assets or liabilities
	Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	The following table summarizes assets and liabilities measured at fair value on a recurring basis at September 30, 2013 and December 31, 2012, respectively:
			September 30, 2013										December 31, 2012
			Level 1			Level 2			Level 3		Total		Level 1		Level 2		Level 3		Total
	Fair Value Measurements Using:
	Assets
	Derivative asset (warrant)		$	—		$	—		$	—	$	—	$	—	$	50,300	$	—	$	50,300
	Liabilities
	Derivative liabilities		$	—		$	3,948,006		$	—	$	3,948,006	$	—	$	4,497,977	$	—	$	4,497,977
	The table below provides a reconciliation of the beginning and ending balances for the assets and liabilities measured at fair value using observable inputs (Level 2). The table reflects net gains and losses for all financial assets and liabilities categorized as Level 2 as of September 30, 2013 and December 31, 2012.
			$			Number of
						Warrants
	Assets:
	Warrant asset as of December 31, 2012		$	50,300			2,000,000
	Decrease in fair value of warrants (note 8)			(50,300	)		(2,000,000	)
	Warrant asset as of September 30, 2013		$	—			—
	Liabilities:
	Warrant liability as of December 31, 2012		$	4,497,977			2,009,436
	Decrease in fair value of warrants			(549,971	)		—
	Warrant liability as of September 30, 2013		$	3,948,006			2,009,436
	Equipment
	Office and Manufacturing equipment are carried at cost less accumulated depreciation, which is computed on a straight-line basis over their estimated useful lives, generally 3 to ten years.
	Due to the postponement of the U.S. re-launch of ONSOLIS® (note 3), related manufacturing equipment, net, totaling $2.5 million has been deemed idle, and has been reclassified to idle equipment, net in the accompanying condensed consolidated balance sheet as of September 30, 2013. The Company evaluates the carrying value of the idle equipment when events or changes in circumstances indicate the related carrying amount may not be recoverable. The Company has not recorded any impairment of this equipment during the nine months ended September 30, 2013.

Liquidity_and_managements_plan

Liquidity and management's plans	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Liquidity and management's plans	'
	2	Liquidity and management’s plans:
	Since inception, the Company has financed its operations principally from the sale of equity securities, proceeds from short-term borrowings or convertible notes, funded research arrangements and revenue generated as a result of its worldwide license and development agreement with Meda regarding ONSOLIS® and revenue generated as a result of its January 2012 agreement with Endo regarding its BEMA® Buprenorphine product candidate. The Company intends to finance its research and development and commercialization efforts and its working capital needs from existing cash, royalty revenue, new sources of debt financing, existing and new licensing and commercial partnership agreements and, potentially, through the exercise of outstanding Common Stock options and warrants to purchase Common Stock.
	Significant new financing and operating sources during the nine months ended September 30, 2013 consisted of:
		•	approximately $20 million in proceeds from secured loan facility from MidCap Financial SBIC, LP, as agent and lender (“MidCap”);
		•	approximately $1.8 million in net royalties under the Meda agreements; and
		•	approximately $0.3 million in from the exercise of stock options.
	Significant new financing and operating sources during the year ended December 31, 2012 consisted of:
		•	approximately $45 million in upfront and milestone payments from the Endo license agreement (see note 4);
		•	approximately $38.4 million in net proceeds from a registered direct offering of Common Stock and newly designated Series A Non-Voting Convertible Preferred Stock, par value $.001 per share (the “Series A Preferred”) in November 2012;
		•	approximately $2.1 million from the exercise of stock options; and
		•	approximately $0.9 million from the exercise of Common Stock warrants.
	On July 5, 2013, the Company, together with Arius One and Arius Two, entered into a $20 million secured loan facility pursuant to a Credit and Security Agreement (the “Credit Agreement”) with MidCap. The Company received net proceeds in the aggregate amount of $19.9 million and is using the loan proceeds for general corporate purposes or other activities permitted under the Credit Agreement. See note 7.
	At September 30, 2013, the Company had cash and cash equivalents of approximately $38.3 million. The Company used approximately $45 million of cash from operations during the nine months ended September 30, 2013. As of September 30, 2013, the Company had stockholders’ equity of approximately $11 million, versus approximately $49.8 million at December 31, 2012. The Company’s existing cash, supplemented with other expected cash inflows from milestones, royalties and potential warrant exercises, is anticipated by management to be sufficient to fully fund the Company’s operations through the fourth quarter of 2014 at the planned level of expenditures. Certain planned expenditures are discretionary and could be deferred if the Company is required to do so to fund critical operations.
	Accordingly, additional capital may be required to support commercialization activities for BUNAVAIL™, clinical development programs for BEMA® Buprenorphine (the scale of which is being governed in large part by the requirements of the Company’s agreement with Endo), the previously announced reformulation project for and anticipated commercial relaunch of ONSOLIS®, planned development of the Company’s Clonidine Topical Gel product for painful diabetic neuropathy and general working capital. Based on product development timelines and agreements with the Company’s development partners, the ability to scale up or reduce personnel and associated costs are factors considered throughout the product development life cycle. Available resources may be consumed more rapidly than currently anticipated, resulting in the need for additional funding.

Meda_License_Development_and_S

Meda License, Development and Supply Agreements	9 Months Ended
	Sep. 30, 2013
Text Block [Abstract]	'
Meda License, Development and Supply Agreements	'
	3	Meda License, Development and Supply Agreements:
	In August 2006 and September 2007, the Company entered into certain agreements with Meda to develop and commercialize the ONSOLIS® product, a drug treatment for breakthrough cancer pain delivered utilizing the BEMA® technology. The aforementioned agreements relate to the United States, Mexico and Canada (such agreements, the “Meda U.S. Agreements”) and to certain countries in Europe (such agreements, the “Meda EU Agreements”, together with Meda U.S. Agreements, the “Meda Agreements”). They carry license terms that commence on the date of first commercial sale in each respective territory and end on the earlier of the entrance of a generic product to the market or upon expiration of the patents, which begin to expire in 2020.
	The Company determined that upon inception of both the U.S. and EU Meda arrangements all deliverables are to be considered one combined unit of accounting since the fair value of the undelivered license was not determinable and the research and development efforts provided do not have stand-alone value apart from the license. As such, all cash payments from Meda that were related to these deliverables were recorded as deferred revenue. Upon commencement of the license term (date of first commercial sale in each territory), the license and certain deliverables associated with research and development services were deliverable to Meda. The first commercial sale in the U.S. occurred in October 2009. As a result, $59.7 million of the aggregate milestones and services revenue was recognized as revenue. The first commercial sale in a European country occurred in October 2012. As a result, $17.5 million was recognized as revenue, which included $5.0 million in milestones received during the year ended December 31, 2012. At September 30, 2013, there was remaining deferred revenue of $1.3 million which is related to the Meda research and development services. As time progresses, the Company will continue to estimate the time required for ongoing obligations, and adjust the remaining deferred revenue accordingly on a quarterly basis.
	The Company earns royalties based on a percentage of net sales revenue of the ONSOLIS® product. The Company earned $1.8 million and $0 in product royalty revenue for the nine months ended September 30, 2013 and 2012, respectively. The Company has incurred cost of product royalties of approximately $1.7 million and $1.1 million for the nine months ended September 30, 2013 and 2012, respectively, which included minimum royalty expenses that the Company is obligated to pay CDC IV, LLC (“CDC”) and NB Athyrium LLC (“Athyrium”) regardless of actual sales.
	On March 12, 2012, the Company announced the postponement of the U.S. re-launch of ONSOLIS® until the product formulation could be modified to address two appearance issues raised by the FDA following an inspection of the Aveva manufacturing facility where ONSOLIS® is produced. The FDA requested that the Company identify, characterize and address the formation of microscopic crystals and a slight fading of the color during the 24-month shelf life of the product. While these changes do not affect the product’s underlying integrity or safety, the FDA believes that the fading of the color in particular may potentially confuse patients, necessitating a modification of the product and product specifications before additional product can be manufactured and distributed. Therefore, the U.S. re-launch and additional manufacturing of ONSOLIS® has been postponed until such product appearance issues have been resolved.
	The crystals and fading issues for ONSOLIS® were presented to the FDA at a favorable meeting in December 2012. A data generation plan to support the approval of a new formulation that resolved both issues was submitted to FDA in March 2013 and followed by initiation of manufacturing in second quarter. Submission of initial stability results for the new formulation is expected early in 2014 with approval by mid-year and re-launch of ONSOLIS® in the second half of 2014.
	On May 21, 2012, the Company announced receipt of a pre-launch milestone payment of $2.5 million from Meda in conjunction with the first country registration and pricing approval for BREAKYL™ (tradename for ONSOLIS® in the EU). A final milestone payment related to the EU of $2.5 million was paid at the time of commercial launch, which occurred in October 2012. BREAKYL™ is commercialized in the EU by Meda.
	On September 13, 2012, the Company executed a Manufacturing, Supply, and License Agreement, effective April 26, 2012, with LTS Lohmann Therapie-Systeme AG (“LTS”), under which LTS will manufacture and supply the Company its BREAKYL™ product for distribution outside of the U.S. and Canada. The Company is required to supply BREAKYL™ product to Meda, Kunwha and TTY pursuant to its obligations under certain license and supply agreements under which Meda, Kunwha, and TTY develop and commercialize the BREAKYL™ product. In conjunction with the agreement, LTS has waived all royalties on products that they produce. This does not preclude royalties that the Company owes to LTS if the Company produces BREAKYL™ with another company.

Endo_License_and_Development_A

Endo License and Development Agreement	9 Months Ended
	Sep. 30, 2013
Text Block [Abstract]	'
Endo License and Development Agreement	'
	4	Endo License and Development Agreement:
	In January 2012, the Company entered into a License and Development Agreement (the “Endo Agreement”) with Endo pursuant to which the Company granted to Endo an exclusive commercial world-wide license to develop, manufacture, market and sell the Company’s BEMA® Buprenorphine product and to complete U.S. development of such product candidate for purposes of seeking FDA approval.
	Pursuant to the Endo Agreement, Endo has obtained all rights necessary to complete the clinical and commercial development of BEMA® Buprenorphine and to sell the product worldwide. Although Endo has obtained all such necessary rights, the Company has agreed under the Endo Agreement to be responsible for the completion of certain clinical trials regarding BEMA® Buprenorphine (and providing clinical trial materials for such trials) necessary to submit a NDA to the FDA in order to obtain approval of BEMA® Buprenorphine in the U.S., in each case pursuant to a development plan set forth in the Endo Agreement (as it may be amended pursuant to the Endo Agreement). The Company is responsible for development activities through the filing of the NDA in the U.S., while Endo is responsible for the development following the NDA submission as well as the manufacturing, distribution, marketing and sales of BEMA® Buprenorphine on a worldwide basis. In addition, Endo is responsible for all filings required in order to obtain regulatory approval of BEMA® Buprenorphine.
	Pursuant to the Endo Agreement, the Company has received (or is expected to receive upon satisfaction of applicable conditions) the following payments (some portion(s) of which will be utilized by the Company to support its development obligations under the Endo Agreement with respect to BEMA® Buprenorphine):
		•	$30 million non-refundable upfront license fee (received January 17, 2012);
		•	up to an aggregate of $95 million in six separate potential milestone payments based on the following pre-defined events: (i) enhancement of intellectual property rights (two milestones aggregating $35 million in potential milestone payments, including $15 million upon issuance of a certain patent covering the product, which was received May 2012), (ii) clinical development (two milestones aggregating $20 million in potential milestone payments) and (iii) regulatory events (two milestones aggregating $40 million in potential milestone payments);
		•	up to an aggregate of $55 million based on the achievement of four separate post-approval sales thresholds; and
		•	sales-based royalties in a particular percentage range on U.S. sales of BEMA® Buprenorphine, and royalties in a lesser range on sales outside the United States, subject to certain restrictions and adjustments.
	The Company has assessed its arrangement with Endo and the Company’s deliverables thereunder at inception to determine: (i) the separate units of accounting for revenue recognition purposes, (ii) which payments should be allocated to which of those units of accounting and (iii) the appropriate revenue recognition pattern or trigger for each of those payments. The assessment requires subjective analysis and requires management to make judgments, estimates and assumptions about whether deliverables within multiple-element arrangements are separable and, if so, to determine the amount of arrangement consideration to be allocated to each unit of accounting.
	At the inception of the Endo arrangement and in accordance with the revenue recognition criteria under ASC Topic 605, the Company determined that the Endo Agreement is a multi-deliverable arrangement under ASC Topic 605 with three deliverables: (1) the license rights related to BEMA® Buprenorphine, (2) services related to obtaining enhanced intellectual property rights through the issuance of a particular patent and (3) clinical development services. The Company concluded that the license delivered to Endo at the inception of the Endo Agreement has stand-alone value under ASC 605-25 because Endo obtained, at the inception of the Endo Agreement, all of the rights and knowledge necessary to fully exploit its license without the Company’s further involvement. It was also determined that there was a fourth deliverable, the provision of clinical trial material (“CTM”). The amounts involved are, however, immaterial and delivered in essentially the same time frame as the clinical development services. Accordingly, the Company has not separately accounted for the CTM deliverable, but considers it part of the clinical development services deliverable.
	The initial non-refundable $30 million license fee was allocated to each of the three deliverables based upon their relative selling prices using best estimates. The analysis of the best estimate of the selling price of the deliverables was based on the income approach, the Company’s negotiations with Endo and other factors, and was further based on management’s estimates and assumptions which included consideration of how a market participant would use the license, estimated market opportunity and market share, the Company’s estimates of what contract research organizations would charge for clinical development services, the costs of clinical trial materials and other factors. Also considered were entity specific assumptions regarding the results of clinical trials, the likelihood of FDA approval of the subject product and the likelihood of commercialization based in part on the Company’s prior agreements with the BEMA® technology.
	Based on this analysis, $15.6 million of the up-front license fee was allocated to the license (which was estimated to have a value significantly in excess of $30 million), and $14.4 million to clinical development services (which is inclusive of the cost of CTM). Although the intellectual property component was considered a separate deliverable, no distinct amount of the up-front payment was assigned to this deliverable because the Company determined the deliverable to be perfunctory. In April 2012, the patent being sought by the Company was granted as described further below, and in May 2012, the applicable intellectual property milestone payment of $15 million was received and recognized as revenue. The amount allocated to the license was recognized as revenue in January 2012.
	The portion of the upfront license fee allocated to the clinical development services deliverable ($14.4 million) is being recognized as those services are performed. The Company estimates that such clinical development services will extend into 2014. Based on the estimated proportion of those services performed through September 30, 2013, $5.2 million was recognized as revenue in fiscal year 2012 and $5.1 million was recognized as revenue during the first nine months of 2013. As a result, $4.1 million remains deferred at September 30, 2013.
	The Company analyzed the milestone payments noted above in accordance with ASC 605-28 to determine if such milestones are substantive. This determination included an analysis of the Company’s performance to achieve each milestone, the enhancement of value of the delivered items, the timing of performance related to the milestone, and the reasonability of the milestone relative to all the deliverables and payment terms. The Company concluded that each of the milestones is substantive under the guidance in ASC 605-28.
	The term of the Endo Agreement shall last, on a country-by-country basis, until the later of: (i) 10 years from the date of the first commercial sale of BEMA® Buprenorphine in a particular country or (ii) the date on which the last valid claim of the Company’s patents covering BEMA® Buprenorphine in a particular country has expired or been invalidated. The Endo Agreement shall be subject to termination: (i) by Endo, at any time, upon a specific amount of prior written notice to the Company, (ii) by Endo and the Company upon mutual written agreement, (iii) by either party upon a material default or breach of the Endo Agreement and such default or breach is not cured within a specified timeframe, (iv) the voluntary or involuntary bankruptcy of either party or (v) by the Company if Endo does not meet certain diligence obligations outside of the United States.
	On February 16, 2012, the Company announced that the U.S. Patent and Trademark Office issued a Notice of Allowance regarding its patent application (No. 13/184306), which patent will extend the exclusivity of the BEMA® drug delivery technology for the Company’s BEMA® Buprenorphine and BUNAVAILTM product candidates from 2020 to 2027. On April 17, 2012, the Company announced that this patent was granted. As a result, pursuant to the Endo Agreement, the Company received a milestone payment from Endo in the amount of $15 million in May 2012. As discussed above, this milestone had been evaluated to be a substantive milestone under ASC 605-28, and therefore was recognized as revenue when the milestone was received.
	The remaining milestone payments are expected to be recognized as revenue as and if they are achieved, except that one milestone is contingently refundable for a period of time. Revenue related to that milestone is expected to be recognized as refund provisions as defined in the agreement expire. Sale threshold payments and sales-based royalties will be recognized as they accrue under the terms of the Endo Agreement.

Arcion_License_Agreement

Arcion License Agreement	9 Months Ended
	Sep. 30, 2013
Text Block [Abstract]	'
Arcion License Agreement	'
	5	Arcion License Agreement:
	On March 26, 2013, the Company entered into a definitive Exclusive License Agreement (the “Arcion Agreement”) with Arcion pursuant to which Arcion agreed to grant to the Company an exclusive commercial world-wide license, with rights of sublicense, under certain patent and other intellectual property rights related to in-process research and development to develop, manufacture, market, and sell gel products containing clonidine (or a derivative thereof), alone or in combination with other active ingredients, for topical administration for the treatment of painful diabetic neuropathy and other indications (the “Arcion Products”).
	Pursuant to the Arcion Agreement, the Company is responsible for using commercially reasonable efforts to develop and commercialize Arcion Products, including the use of such efforts to conduct certain clinical trials within certain time frames.
	Upon execution of the Arcion Agreement, the Company issued to Arcion 500,516 unregistered shares of Common Stock (having a fair market value of $2.1 million), which shares are subject to a nine month lock-up and certain limitations on sale thereafter. The issuance of such shares (delivered April 2013) was exempt from registration under the Securities Act of 1933, as amended, in reliance on Section 4(2) thereof. In addition, the Company is required to make the following payments to Arcion:
		•	$2.5 million upon filing and acceptance by the FDA of an NDA with respect to an Arcion Product, payable at the Company’s option, in cash or unregistered shares of Common Stock (with such shares also being subject to a nine month lock-up and certain limitations on sale thereafter); and
		•	up to a potential $60 million in cash payments upon achieving certain pre-determined sales thresholds in the U.S., none of which occur prior to achieving at least $200 million in U.S. net sales.
	In addition, the Company shall pay Arcion $35 million in cash on initial FDA approval of an Arcion Product, unless; (i) the Company does not receive at least $70 million in FDA approval-related milestone payments from its US sublicensees (if any sublicenses are involved) with respect to the Arcion Product, in which case the Company shall pay Arcion a prorated amount between $17.5 million and $35 million based on the total amount of such milestone payments received by the Company and its affiliates from its sublicenses (if any sublicenses are involved); or (ii) the FDA requires or recommends the performance of a capsaicin challenge test as a precondition or precursor to the prescribing of the Arcion Product (as a condition of approval, a labeling requirement, or otherwise), in which case such milestone shall be reduced to $17.5 million, but the first and second sales threshold payments described above shall each be increased by $8 million.
	All milestone payments due Arcion under the Arcion Agreement are payable only once each.
	In addition to the milestones set forth above, the Company will pay Arcion:
		•	a low single digit royalty on the Company’s and its affiliates’ net sales of Arcion Products in the U.S.;
		•	a low double digit percentage of all sales-based payments received by the Company and its affiliates with respect to sublicensees’ sales of Arcion Products in the U.S.;
		•	a low single digit royalty on all net sales of Arcion Products outside the U.S.; and
		•	a low double digit percentage of all milestone payments received by the Company and its affiliates from their sublicensees that are triggered by the receipt of regulatory approval of the Arcion Product in certain jurisdictions outside of the U.S.
	The aforementioned sales royalties are subject to certain reductions, on a country-by-country and product-by-product basis, under certain agreed upon circumstances. In addition, in the event the amount due upon FDA approval of the Arcion Product in the U.S. is less than $35 million for any reason other than an FDA requirement or recommendation of a capsaicin challenge test, as described above, the Company shall pay Arcion a portion of any milestone payments received by the Company and its affiliates from their sublicensees on the basis of any events occurring in the U.S. following FDA approval but prior to (and including) first commercial sale of an Arcion Product in the U.S., and certain of the payments to Arcion referred to above shall also be subject to upward adjustment (with such upward adjustments payable in the form of cash or unregistered shares of the Company’s Common Stock, as elected solely by the Company), until such time as the sum of all such additional payments and upward adjustments (including the value of any issuances of stock, if elected by the Company) and the initial amount paid on the initial FDA approval totals $35 million.
	The term of the Arcion Agreement continues, on a country-by-country and product-by-product basis, until the earlier of (i) the expiration of the royalty term for a particular Arcion Product in a particular country or (ii) the effective date of termination by either party pursuant to customary termination provisions. The royalty term for any given country is the later of (i) the first date there are no valid claims against any Arcion patent, (ii) expiration of patent exclusivity or (iii) tenth anniversary of the first commercial sale. Further, the Company may, in its sole discretion, terminate the Arcion Agreement upon certain notice to Arcion. Upon expiration of the Agreement pursuant to clause (i) above with respect to a particular Arcion Product and country, the Company and its affiliates shall have the perpetual, unrestricted, irrevocable, fully-paid, royalty-free exclusive right, with rights of sublicense, to make, have made, use, sell, offer for sale, and import such Arcion Product in such country.
	In conjunction with this transaction, the March 2013 payment to Arcion of $2.1 million in unregistered Common Stock was for in-process research and development and has been recorded as research and development expense in the condensed consolidated statement of operations for the nine months ended September 30, 2013.

Other_License_Agreements_and_A

Other License Agreements and Acquired Product Rights	9 Months Ended
	Sep. 30, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'
Other License Agreements and Acquired Product Rights	'
	6	Other License Agreements and Acquired Product Rights:
	Kunwha License Agreement
	In May 2010, the Company entered into a License and Supply Agreement (the “Kunwha License Agreement”) with Kunwha to develop, manufacture, sell and distribute the Company’s BEMA® Fentanyl product in the Republic of Korea (the “Kunwha Territory”). BEMA® Fentanyl is marketed as ONSOLIS® in North America. The Kunwha License Agreement is for a term beginning on May 26, 2010 until the date of expiration of the patents, or July 23, 2027, whichever is later.
	Under the terms of the Kunwha License Agreement, Kunwha was granted exclusive licensing rights for BEMA® Fentanyl in the Kunwha Territory, while the Company will retain all other licensing rights to the Licensed Product not previously granted to third parties. Kunwha paid to the Company an upfront payment of $0.3 million (net of taxes approximating $0.25 million) and will be responsible to make certain milestone payments which could aggregate up to $1.3 million (net of taxes approximating $1.1 million).
	In addition, Kunwha will pay royalties to the Company based on Net Sales (as defined in the Kunwha License Agreement) and will purchase all supplies of BEMA® Fentanyl from the Company.
	Kunwha will be responsible for payment of all costs associated with BEMA® Fentanyl in the Kunwha Territory. Kunwha and the Company will own any Improvements (as defined in the Kunwha License Agreement) made exclusively by such party with respect to BEMA® Fentanyl and will jointly own any Improvements that are the product of collaboration.
	TTY License and Supply Agreement
	On October 7, 2010, the Company announced a license and supply agreement with TTY for the exclusive rights to develop and commercialize BEMA® Fentanyl in the Republic of China, Taiwan. The agreement results in potential milestone payments to the Company of up to $1.3 million, which includes an upfront payment of $0.3 million, which was recorded as contract revenue in 2010. In addition, the Company will receive an ongoing royalty based on net sales. TTY will be responsible for the regulatory filing of BEMA® Fentanyl in Taiwan as well as future commercialization in that territory. The term of the agreement with TTY is for the period from October 4, 2010 until the date fifteen (15) years after first commercial sale unless the agreement is extended in writing or earlier terminated as provided for in the agreement.
	On November 7, 2011, the Company announced that TTY had submitted an NDA for marketing authorization of BEMA® Fentanyl to the Taiwan Food and Drug Administration. This triggered a milestone payment to the Company of approximately $0.3 million, which was received November 2011 and recorded as contract revenue in 2011.
	On July 29, 2013, the Company announced the regulatory approval of BEMA® Fentanyl in Taiwan, where the product will be marketed under the brand name PAINKYL™. The approval in Taiwan resulted in a milestone payment of $0.3 million to the Company, which was received in the third quarter 2013, and recorded as contract revenue in the accompanying condensed consolidated statement of operations.

MidCap_Secured_Loan_Facility

MidCap Secured Loan Facility	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
MidCap Secured Loan Facility	'
	7	MidCap Secured Loan Facility:
	On July 5, 2013, the Company, Arius One and Arius Two (the “Borrowers”) entered into a $20 million secured loan facility (the “Loan Transaction” and such loan, the “Loan”) with MidCap as agent and lender pursuant to the terms and conditions of the Credit Agreement. The Company received net proceeds in the aggregate amount of $19.9 million and will use the Loan proceeds for general corporate purposes or other activities of the Borrower permitted under the Credit Agreement.
	In addition, pursuant to the Loan Transaction, the Company issued to MidCap a warrant (the “MidCap Warrant”) to purchase 357,356 unregistered shares of Common Stock, which warrant has an exercise price of $4.20 per share, the 20-day volume-weighted average share price of the Common Stock prior to the closing of the Loan. The MidCap Warrant is exercisable for a term of five (5) years and contains cashless exercise provisions and customary, anti-dilution protection provisions. The proceeds of the secured loan facility were allocated to the note payable and Midcap warrants (which qualified for equity accounting) based on their relative fair values, as follows:
	Note payable		$	19,013,648
	MidCap warrant			986,352
	Total proceeds		$	20,000,000
	The resulting debt discount is being amortized to interest expense over the 3 year life of the loan.
	The fair value of the warrants was determined based upon the Black Scholes valuation model using the following key assumptions:
	Market price of stock		$	4.41
	Term of warrant			5 years
	Volatility			81.05	%
	Risk free interest rate			2.9	%
	The Loan has a term of 36 months with interest only payments until February 1, 2014. The interest rate is 8.45% plus a LIBOR floor of 0.5% (total of 8.95% at September 30, 2013). Upon execution of the Credit Agreement, the Company paid to MidCap a closing fee of 0.5% of the aggregate Loan amount. Upon repayment in full of the Loan, the Company is obligated to make a final payment fee equal to 3.5% of the aggregate Loan amount. In addition, the Company may prepay all or any portion of the Loan at any time subject to a prepayment premium of: (i) 5% of the Loan amount prepaid in the first year of the Loan and (ii) 3% of the Loan amount prepaid in each year thereafter. In addition, if the Company receives the second of two anticipated database lock milestone payments (the “Database Lock Payments”) from Endo in connection with the Endo Agreement, the Company may prepay 50% of the principal amount of the Loan then outstanding and, concurrently and at the Company’s election, either: (i) pay to MidCap a cash prepayment fee of 2% of the principal amount of the Loan and all obligations thereunder outstanding as of the date of prepayment or (ii) issue to MidCap a warrant (in a form substantially similar to the MidCap Warrant) to purchase shares of Common Stock equal to 2.0% of the prepayment amount, with the number of shares being calculated using the Black-Scholes pricing model.
	The obligations of the Borrowers under the Credit Agreement are secured by a first priority lien in favor of MidCap on substantially all of the Borrowers’ existing and after-acquired assets, but excluding certain of the Borrowers’ intellectual property and general intangible assets of the Borrowers (but not any proceeds thereof). The obligations of the Company under the Loan Agreement are also secured by a first priority lien on the equity interests held by the Company in Arius One, Arius Two and BND. The Borrowers entered into customary pledge and intellectual property security agreements to evidence the security interest in favor of MidCap.
	Under the Credit Agreement, the Borrowers are subject to affirmative covenants which are customary for financings of this type, including, but not limited to, the obligations of the Borrowers to: (i) maintain good standing and governmental authorizations, (ii) provide certain information and notices to MidCap, (iii) deliver monthly and annual financial statements to MidCap, (iv) maintain insurance, (v) discharge all taxes, (vi) protect their intellectual property and (vii) generally protect the collateral granted to MidCap.
	The Borrowers are also subject to negative covenants customary for financings of this type, including, but not limited to, that without the prior consent of Midcap, they may not: (i) enter into a merger or consolidation or certain change of control events, (ii) incur liens on the collateral, (iii) incur additional indebtedness, (iii) dispose of any property, (iv) amend material agreements or organizational documents, (v) change their jurisdictions of organization or their organizational structures or types, (vi) declare or pay dividends (other than dividends payable solely in Common Stock), (vii) make certain investments or acquisitions, or (viii) enter into certain transactions with affiliates, in each case subject to certain exceptions provided for in the Credit Agreement, including exceptions that allow the Borrowers to acquire additional products and to enter into licenses and similar agreements provided certain conditions are met.
	The Credit Agreement provides that events of default include: (i) failure to make payment of principal or interest on the Loan when required, (ii) failure to perform obligations under the Credit Agreement and related documents, (iii) defaults in other indebtedness and breaches of material agreements of the Borrowers, (iv) if any Borrower shall generally not pay its debts as such debts become due and similar insolvency matters, (v) material adverse changes to the Borrowers (subject to a 10-day notice and cure period), (vi) if the Company ceases to be a publicly-listed and reporting company, (vii) failure to receive the Database Lock Payments by June 30, 2014, and (viii) certain other events, including certain adverse actions taken by the Food and Drug Administration or other governmental authorities. Upon an event of default, the Borrower’s obligations under the Credit Agreement may, or in the event of insolvency or bankruptcy will automatically, be accelerated. Upon the occurrence of any event of default, the Borrower’s obligations under the Credit Agreement will bear interest at a rate equal to the lesser of: (i) 4% above the rate of interest applicable to such obligations immediately prior to the occurrence of the event of default and (ii) the maximum rate allowable under law. The balance of the secured loan facility due to MidCap as of September 30, 2013 is $20 million, and is recorded in the accompanying condensed consolidated balance sheet.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	8	Related Party Transactions:
	In 2009, as part of a settlement arrangement, the Company received a warrant from Accentia Biopharmaceuticals, Inc., a related party (“Accentia”), to purchase two million shares of common stock of Biovest International, Inc. (“Biovest”) held by Accentia. Biovest was a majority-owned subsidiary of Accentia. During the nine months ending September 30, 2013, Biovest filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court. On July 9, 2013, the plan became effective, which canceled all outstanding common stock and warrants. As a result, the warrants had no value as of September 30, 2013 and the reduction of value is included in derivative (loss) gain in the condensed consolidated statement of operations for the three and nine months ended September 30, 2013.

Derivative_Financial_Instrumen

Derivative Financial Instruments	9 Months Ended
	Sep. 30, 2013
Derivative Instruments And Hedging Activities Disclosure [Abstract]	'
Derivative Financial Instruments	'
	9	Derivative Financial Instruments:
	The Company generally does not use derivative instruments to hedge exposures to cash-flow risks or market-risks that may affect the fair values of its financial instruments. However, certain other financial instruments, such as warrants and embedded conversion features that are indexed to the Company’s Common Stock, are classified as liabilities when either: (a) the holder possesses rights to net-cash settlement or (b) physical or net-share settlement is not within the control of the Company. In such instances, net-cash settlement is assumed for financial accounting and reporting, even when the terms of the underlying contracts do not provide for net-cash settlement. Such financial instruments are initially recorded at fair value estimated on the settlement date using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate, and then adjusted to fair value at the close of each reporting period.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Stockholders' Equity	'
	10	Stockholders’ Equity:
	Stock-based compensation:
	During the nine months ended September 30, 2013, a total of 177,110 options to purchase Common Stock with an aggregate fair market value of approximately $0.5 million were granted to Company employees. The options granted have a term of 10 years from the grant date and vest ratably over a three year period. The fair value of each option is amortized as compensation expense evenly through the vesting period. The fair value of each option award is estimated on the grant date using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatilities are based on implied volatilities from historical volatility of the Common Stock, and other factors estimated over the expected term of the options. The expected term of options granted is derived using the “simplified method” which computes expected term as the average of the sum of the vesting term plus contract term. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. The weighted average for key assumptions used in determining the fair value of options granted during the nine months ended September 30, 2013 follows:
	Expected price volatility		78.76-81.65%
	Risk-free interest rate		0.81-1.20%
	Weighted average expected life in years		6 years
	Dividend yield		—
	Option activity during the nine months ended September 30, 2013 was as follows:
			Number of			Weighted		Aggregate
			Shares			Average		Intrinsic
						Exercise		Value
						Price
						Per Share
	Outstanding at January 1, 2013			4,279,919		$	3.7
	Granted in 2013:
	Officers and Directors			—			—
	Others			177,110			4.38
	Exercised			(102,827	)		3.38
	Forfeitures			(218,431	)		2.71
	Outstanding at September 30, 2013			4,135,771		$	3.79	$	7,590,138
	Options outstanding at September 30, 2013 are as follows:
	Range of Exercise Prices		Number			Weighted		Weighted		Aggregate
			Outstanding			Average		Average		Intrinsic
						Remaining		Exercise		Value
						Contractual		Price
						Life (Years)
	$1.00 – 5.00			3,229,271			5.63	$	3.08
	$5.01 – 10.00			906,500			3.91	$	6.3
				4,135,771						$	7,590,138
	Options exercisable at September 30, 2013 are as follows:
	Range of Exercise Prices		Number			Weighted		Weighted		Aggregate
			Exercisable			Average		Average		Intrinsic
						Remaining		Exercise		Value
						Contractual		Price
						Life (Years)
	$1.00 – 5.00			2,657,674			4.94	$	3
	$5.01 – 10.00			906,500			3.91	$	6.3
				3,564,174						$	6,475,065
	The weighted average grant date fair value of options granted during the nine months ended September 30, 2013 was $2.97. There were no options granted during the nine months ended September 30, 2013 whose exercise price was lower than the estimated market price of the stock at the grant date. A summary of the status of the Company’s non-vested stock options as of January 1, 2013, and changes during the nine months ended September 30, 2013 is summarized as follows:
	Nonvested Shares		Shares			Weighted		Aggregate
						Average		Intrinsic
						Grant  Date		Value
						Fair Value
	Nonvested at January 1, 2013			854,640
	Granted			177,110
	Vested			(305,872	)
	Forfeited			(154,281	)
	Nonvested at September 30, 2013			571,597		$	2.41	$	1,115,073
	As of September 30, 2013, there was approximately $7.4 million of unrecognized compensation cost related to unvested share-based compensation awards, including restricted stock units (“RSUs”), granted. These costs will be expensed through 2019.
	Warrants:
	The Company has granted warrants to purchase shares of Common Stock. Warrants may be granted to affiliates in connection with certain agreements. Warrants outstanding at September 30, 2013, all of which are exercisable are as follows:
	Range of Exercise Prices		Number			Weighted		Weighted		Aggregate
			Outstanding			Average		Average		Intrinsic
						Remaining		Exercise		Value
						Contractual		Price
						Life (Years)
	$0.01 – 5.00			2,366,792			0.97	$	3.93	$	3,560,668
	MidCap:
	The Company issued warrants to purchase 357,356 shares of Common Stock at a price of $4.20 in connection with a loan financing in July 2013. The warrants had a fair value of $1 million at the date of the grant.
	Restricted Stock Units:
	During the nine months ended September 30, 2013, a total of 1,078,336 RSUs with a fair market value of approximately $4.5 million were granted to members of the Company’s senior management. The fair value of restricted units is determined using quoted market prices of the Common Stock and the number of shares expected to vest. These RSUs were issued under the Company’s 2011 Equity Incentive Plan, as amended, and vest in equal installments over three years. This grant was in lieu of the 2012 annual option grant typically given to senior management in order to bring the percentage ownership of senior management in line with the senior management of companies in the Company’s peer group.
	In addition, in June 2013, the Company issued 3,125 RSUs with a fair value of $0.01 million to a new board member, which vested immediately. The Company also issued in August 2013, a total of 118,853 RSUs to board members with a fair value of approximately $0.6 million, of which 63,853 RSUs vested immediately and the remaining 55,000 vest in August 2014.
	Preferred Stock
The Company has authorized five million “blank check” shares of $.001 par value convertible preferred stock. At September 30, 2013, 2,709,300 shares of Series A Preferred were outstanding.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	11	Commitments and contingencies:
	Litigation Related To ONSOLIS®
	In March 2012, the Company announced that the New Jersey Federal Court granted a stay of further litigation in the patent infringement lawsuit previously filed by MonoSol Rx, LLC (“MonoSol”) against the Company and its ONSOLIS® commercial partners. The court ordered that the case would be stayed pending resolution by the United States Patent and Trademark Office (“USPTO”) of reexamination proceedings and follows the recent rejection by the USPTO of all claims in all three patents asserted by MonoSol against the Company and its commercial partners for ONSOLIS®.
	In July 2012, a Reexamination Certificate for MonoSol’s ‘292 Patent in its amended form was issued by the USPTO. The USPTO also issued a second Office Action closing prosecution on MonoSol’s ‘588 Patent. The Action rejects all claims as anticipated or obvious for a second time. It also rejects the amended claims proposed by MonoSol as unclear and lacking support. In August 2012, a Reexamination Certificate for MonoSol’s ‘891 Patent in its amended form was issued.
	On January 23, 2013, the USPTO issued a Right of Appeal Notice, rejecting all claims of the ‘588 Patent and closing reexamination proceedings. This action confirms that all claims of this patent are also invalid, but unlike ‘292 and ‘891, the USPTO has not found that any amended or narrower claims should be granted. On February 22, 2013, MonoSol filed both a Notice of Appeal to the Board of Patent Appeals and Interferences and a Request for Continuing Examination of the ‘588 Patent. Subsequently, on July 3, 2013, the USPTO denied MonoSol’s February 22, 2013 Request to Continue Examination.
	Inter partes reviews, a new USPTO process to review the patentability of one or more claims of patents, was enacted in September, 2012. As such, on June 12, 2013, despite the Company’s previously noted success in the prior ex parte reexaminations for the “292” and “891” patents, the Company availed themselves of this new process and filed requests for inter partes reviews on the narrowed, yet reexamined, patents, the ‘292C1 and ‘891C1 Patents, to challenge their validity and continue to strengthen the Company’s position. This inter partes review process allows the Company to actively participate in the reviews and address any of MonoSol’s arguments and representations made during the review process, which heightens the Company’s ability to invalidate these patents. After reviewing Monosol’s Appeal Brief (filed June 24, 2013) and the Company’s Respondent’s Brief (filed July 24, 2013), the USPTO formally initiated the appeals process with the Examiner’s Answer on August 8, 2013, which affirmed the rejection of all the claims in the ‘588 Patent.
	Based on the Company’s original assertion that its proprietary manufacturing process for ONSOLIS® does not infringe on patents held by MonoSol, and the denial and subsequent narrowing of the claims on the two reissued patents MonoSol has asserted against the Company while the third has had all claims rejected by the USPTO, the Company remains very confident in their original stated position regarding this matter. Thus far the Company has proven that the “original” ‘292 and ‘891patents in light of their reissuance with fewer and narrower claims were indeed invalid and the third and final patent, ‘588, has had all claims rejected and appears to have had a similar fate. Importantly, the Company will continue to defend this case vigorously, and anticipates that MonoSol’s claims against the Company will ultimately be rejected.
	Litigation Related To BUNAVAILTM
	On October 29, 2013, Reckitt Benckiser, Inc. RB Pharmaceuticals Limited, and MonoSol RX, LLC (collectively, the “RB Plaintiffs”) filed an action against the Company relating to the Company’s BUNAVAIL™ product in the United States District Court for the Eastern District of North Carolina for alleged patent infringement. BUNAVAIL™ is a proposed treatment for opioid dependence. The RB Plaintiffs claim that the formulation for BUNAVAIL™, which has never been disclosed publicly, infringes its patent (United States Patent No. 8,475,832). The Company strongly refutes as without merit the RB Plaintiffs’ assertion of patent infringement and will vigorously defend the lawsuit.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Overview	'
	Overview:
	The accompanying unaudited condensed consolidated financial statements of BioDelivery Sciences International, Inc., a Delaware corporation, together with its wholly-owned subsidiaries, Arius Pharmaceuticals, Inc., a Delaware corporation (“Arius One”), and Arius Two, Inc., a Delaware corporation (“Arius Two”), and its majority-owned, inactive subsidiary, Bioral Nutrient Delivery, LLC, a Delaware limited liability company (“BND”, together with Arius One and Arius Two, collectively, the “Company” or “we”, “us” or similar terminology) have been prepared by the Company without audit. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, 2013, and for all periods presented, have been made. All intercompany accounts and transactions have been eliminated.
	Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the Securities and Exchange Commission (“SEC”) rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2012, which are included in the Company’s 2012 Annual Report on Form 10-K, filed with the SEC on March 18, 2013 (the “2012 Annual Report”). The accompanying condensed consolidated balance sheet at December 31, 2012 has been derived from the audited financial statements at that date, but does not include all information and notes required by GAAP for complete financial statements.
	The Company is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. The Company is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction.
	The Company’s pain franchise currently consists of four products, three of which utilize the patented BioErodible MucoAdhesive (“BEMA”) drug delivery technology, a thin film applied to the inner lining of the cheek. ONSOLIS® (fentanyl buccal soluble film) is approved in the U.S., Canada, E.U. (where it is marketed as BREAKYL) and Taiwan (where it is marketed as PAINKYL™), for the management of breakthrough pain in opioid tolerant, adult patients with cancer. The commercial rights to ONSOLIS® are licensed to Meda AB (“Meda”) for all territories worldwide except for Taiwan (licensed to TTY Biopharm Co. Ltd. (“TTY”)) and South Korea (licensed to Kunwha Pharmaceutical Co., Ltd. (“Kunwha”)). The Company’s second pain product using the BEMA® technology, BEMA® Buprenorphine, is in Phase 3 clinical trials for the treatment of moderate to severe chronic pain and is licensed on a worldwide basis to Endo Health Solutions, Inc. (“Endo”). Additionally, in October 2013, the U.S. Food and Drug Administration (“FDA”) accepted the Company’s New Drug Application for BUNAVAIL™ (buprenorphine naloxone buccal film), a high dose formulation of buprenorphine in combination with naloxone for the maintenance treatment of opioid dependence. FDA’s decision on the BUNAVAIL™ New Drug Application (“NDA”) is due in June 2014. The Company’s fourth pain product in development is Clonidine Topical Gel for the treatment of painful diabetic neuropathy, which was licensed from Arcion Therapeutics, Inc. (“Arcion”) in March 2013.
	The results of operations for the nine month period ended September 30, 2013 are not necessarily indicative of results that may be expected for any other interim period or for the full fiscal year. Readers of this Quarterly Report are strongly encouraged to review the risk factors relating to the Company which are set forth in the 2012 Annual Report.
	BDSI® and BEMA® are registered trademarks of the Company. The BioDelivery Sciences logo and BUNAVAILTM are trademarks owned by the Company. ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc. BREAKYL™ is a trademark owned by Meda Pharma GmbH & Co. KG. PAINKYL™ is a trademark owned by TTY Biopharm. All other trademarks and tradenames are owned by their respective owners.
	As used herein, the term “Common Stock” means the Company’s common stock, par value $.001 per share.
Fair Value of Financial Assets and Liabilities	'
	Fair value of financial assets and liabilities:
	The Company measures the fair value of financial assets and liabilities in accordance with GAAP which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.
	GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. GAAP describes three levels of inputs that may be used to measure fair value:
	Level 1 – quoted prices in active markets for identical assets or liabilities
	Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	The following table summarizes assets and liabilities measured at fair value on a recurring basis at September 30, 2013 and December 31, 2012, respectively:
		September 30, 2013										December 31, 2012
		Level 1			Level 2			Level 3		Total		Level 1		Level 2		Level 3		Total
	Fair Value Measurements Using:
	Assets
	Derivative asset (warrant)	$	—		$	—		$	—	$	—	$	—	$	50,300	$	—	$	50,300
	Liabilities
	Derivative liabilities	$	—		$	3,948,006		$	—	$	3,948,006	$	—	$	4,497,977	$	—	$	4,497,977
	The table below provides a reconciliation of the beginning and ending balances for the assets and liabilities measured at fair value using observable inputs (Level 2). The table reflects net gains and losses for all financial assets and liabilities categorized as Level 2 as of September 30, 2013 and December 31, 2012.
		$			Number of
					Warrants
	Assets:
	Warrant asset as of December 31, 2012	$	50,300			2,000,000
	Decrease in fair value of warrants (note 8)		(50,300	)		(2,000,000	)
	Warrant asset as of September 30, 2013	$	—			—
	Liabilities:
	Warrant liability as of December 31, 2012	$	4,497,977			2,009,436
	Decrease in fair value of warrants		(549,971	)		—
	Warrant liability as of September 30, 2013	$	3,948,006			2,009,436
Equipment	'
	Equipment
	Office and Manufacturing equipment are carried at cost less accumulated depreciation, which is computed on a straight-line basis over their estimated useful lives, generally 5 to ten years.
	Due to the postponement of the U.S. re-launch of ONSOLIS® (note 3), related manufacturing equipment, net, totaling $2.5 million has been deemed idle, and has been reclassified to idle equipment, net in the accompanying condensed consolidated balance sheet as of September 30, 2013. The Company evaluates the carrying value of the idle equipment when events or changes in circumstances indicate the related carrying amount may not be recoverable. The Company has not recorded any impairment of this equipment during the nine months ended September 30, 2013.

Basis_of_Presentation_Tables

Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	The following table summarizes assets and liabilities measured at fair value on a recurring basis at September 30, 2013 and December 31, 2012, respectively:
		September 30, 2013										December 31, 2012
		Level 1			Level 2			Level 3		Total		Level 1		Level 2		Level 3		Total
	Fair Value Measurements Using:
	Assets
	Derivative asset (warrant)	$	—		$	—		$	—	$	—	$	—	$	50,300	$	—	$	50,300
	Liabilities
	Derivative liabilities	$	—		$	3,948,006		$	—	$	3,948,006	$	—	$	4,497,977	$	—	$	4,497,977
Reconciliation of Beginning and Ending Balances for Assets and Liabilities Measured at Fair Value Using Observable Inputs	'
	The table below provides a reconciliation of the beginning and ending balances for the assets and liabilities measured at fair value using observable inputs (Level 2). The table reflects net gains and losses for all financial assets and liabilities categorized as Level 2 as of September 30, 2013 and December 31, 2012.
		$			Number of
					Warrants
	Assets:
	Warrant asset as of December 31, 2012	$	50,300			2,000,000
	Decrease in fair value of warrants (note 8)		(50,300	)		(2,000,000	)
	Warrant asset as of September 30, 2013	$	—			—
	Liabilities:
	Warrant liability as of December 31, 2012	$	4,497,977			2,009,436
	Decrease in fair value of warrants		(549,971	)		—
	Warrant liability as of September 30, 2013	$	3,948,006			2,009,436

MidCap_Secured_Loan_Facility_T

MidCap Secured Loan Facility (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Schedule Showing Allocation of Secured Loan Facility to Notes Payable and Midcap Warrants	'
	The proceeds of the secured loan facility were allocated to the note payable and Midcap warrants (which qualified for equity accounting) based on their relative fair values, as follows:
	Note payable	$	19,013,648
	MidCap warrant		986,352
	Total proceeds	$	20,000,000
Schedule of Fair Value of Warrants Based Upon the Black Scholes Valuation Model Assumptions	'
	The fair value of the warrants was determined based upon the Black Scholes valuation model using the following key assumptions:
	Market price of stock	$	4.41
	Term of warrant		5 years
	Volatility		81.05	%
	Risk free interest rate		2.9	%

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Equity [Abstract]	'
Weighted Average for Key Assumptions Used in Determining Fair Value of Options Granted	'
	The weighted average for key assumptions used in determining the fair value of options granted during the nine months ended September 30, 2013 follows:
	Expected price volatility	78.76-81.65%
	Risk-free interest rate	0.81-1.20%
	Weighted average expected life in years	6 years
	Dividend yield	—
Summary of Stock Option Activity	'
	Option activity during the nine months ended September 30, 2013 was as follows:
		Number of			Weighted		Aggregate
		Shares			Average		Intrinsic
					Exercise		Value
					Price
					Per Share
	Outstanding at January 1, 2013		4,279,919		$	3.7
	Granted in 2013:
	Officers and Directors		—			—
	Others		177,110			4.38
	Exercised		(102,827	)		3.38
	Forfeitures		(218,431	)		2.71
	Outstanding at September 30, 2013		4,135,771		$	3.79	$	7,590,138
Summary of Stock Options Outstanding	'
	Options outstanding at September 30, 2013 are as follows:
	Range of Exercise Prices	Number			Weighted		Weighted		Aggregate
		Outstanding			Average		Average		Intrinsic
					Remaining		Exercise		Value
					Contractual		Price
					Life (Years)
	$1.00 – 5.00		3,229,271			5.63	$	3.08
	$5.01 – 10.00		906,500			3.91	$	6.3
			4,135,771						$	7,590,138
Summary of Stock Options Exercisable	'
	Options exercisable at September 30, 2013 are as follows:
	Range of Exercise Prices	Number			Weighted		Weighted		Aggregate
		Exercisable			Average		Average		Intrinsic
					Remaining		Exercise		Value
					Contractual		Price
					Life (Years)
	$1.00 – 5.00		2,657,674			4.94	$	3
	$5.01 – 10.00		906,500			3.91	$	6.3
			3,564,174						$	6,475,065
Summary of Non-Vested Stock Options	'
	A summary of the status of the Company’s non-vested stock options as of January 1, 2013, and changes during the nine months ended September 30, 2013 is summarized as follows:
	Nonvested Shares	Shares			Weighted		Aggregate
					Average		Intrinsic
					Grant  Date		Value
					Fair Value
	Nonvested at January 1, 2013		854,640
	Granted		177,110
	Vested		(305,872	)
	Forfeited		(154,281	)
	Nonvested at September 30, 2013		571,597		$	2.41	$	1,115,073
Summary of Warrants Outstanding to Purchase Common Stock	'
	Warrants outstanding at September 30, 2013, all of which are exercisable are as follows:
	Range of Exercise Prices	Number			Weighted		Weighted		Aggregate
		Outstanding			Average		Average		Intrinsic
					Remaining		Exercise		Value
					Contractual		Price
					Life (Years)
	$0.01 – 5.00		2,366,792			0.97	$	3.93	$	3,560,668

Basis_of_Presentation_Addition

Basis of Presentation - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012
	Product
Basis Of Presentation [Line Items]	'	'	'
Number of products under pain franchise	4	'	'
Common Stock, par value	$0.00	$0.00	$0.00
Idle equipment, net	$2,469,178	'	'
Impairment Charges	$0	'	'
Minimum [Member]	'	'	'
Basis Of Presentation [Line Items]	'	'	'
Estimated useful lives of equipment	'3 years	'	'
Maximum [Member]	'	'	'
Basis Of Presentation [Line Items]	'	'	'
Estimated useful lives of equipment	'10 years	'	'

Basis_of_Presentation_Summary_

Basis of Presentation - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (Fair Value, Measurements, Recurring [Member], USD $)	Sep. 30, 2013	Dec. 31, 2012
Assets	'	'
Derivative asset (warrant)	'	$50,300
Liabilities	'	'
Derivative liabilities	3,948,006	4,497,977
Level 1 [Member]	'	'
Assets	'	'
Derivative asset (warrant)	'	'
Liabilities	'	'
Derivative liabilities	'	'
Level 2 [Member]	'	'
Assets	'	'
Derivative asset (warrant)	'	50,300
Liabilities	'	'
Derivative liabilities	3,948,006	4,497,977
Level 3 [Member]	'	'
Assets	'	'
Derivative asset (warrant)	'	'
Liabilities	'	'
Derivative liabilities	'	'

Basis_of_Presentation_Reconcil

Basis of Presentation - Reconciliation of Beginning and Ending Balances of Assets and Liabilities Measured at Fair Value Using Significant Observable Inputs (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Assets [Member]	'
Basis Of Presentation [Line Items]	'
Warrant asset as of December 31, 2012	$50,300
Decrease in fair value of warrants	-50,300
Warrant asset as of September 30, 2013	'
Warrant asset as of December 31, 2012	2,000,000
Decrease in fair value of warrants	-2,000,000
Warrant asset as of September 30, 2013	'
Liabilities [Member]	'
Basis Of Presentation [Line Items]	'
Warrant liability as of December 31, 2012	4,497,977
Decrease in fair value of warrants	-549,971
Warrant liability as of September 30, 2013	$3,948,006
Warrant liability as of December 31, 2012	2,009,436
Decrease in fair value of warrants	'
Warrant liability as of September 30, 2013	2,009,436

Recovered_Sheet1

Liquidity and Management's Plans - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 05, 2013	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011	Nov. 30, 2012
								Series A Non-Voting Convertible Preferred Stock [Member]
Liquidity and Management's Plans [Line Items]	'	'	'	'	'	'	'	'
Proceeds from secured loan facility from Midcap	'	'	'	$20,000,000	'	'	'	'
Net royalties under the meda agreements	'	924,272	'	1,779,373	'	'	'	'
Exercise of Common Stock options	'	'	'	347,434	1,873,397	2,100,000	'	'
Upfront and milestone payments from Endo license agreement	'	'	'	'	'	45,000,000	'	'
Preferred Stock, par value	'	$0.00	'	$0.00	'	$0.00	'	$0.00
Net proceeds from registered direct offering of Common Stock and newly designated Series	'	'	'	'	'	38,400,000	'	'
Exercise of Common Stock warrants	'	'	'	'	135,000	900,000	'	'
Secured loan facility	20,000,000	'	'	'	'	'	'	'
Net proceeds in the aggregate amount	19,900,000	'	'	'	'	'	'	'
Cash and cash equivalents	'	38,296,062	31,319,153	38,296,062	31,319,153	63,189,307	10,750,205	'
Cash from operations	'	'	'	-44,940,535	19,650,639	'	'	'
Stockholders' equity	'	$11,046,777	'	$11,046,777	'	$49,777,213	'	'

Meda_License_Development_and_S1

Meda License, Development and Supply Agreements - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Oct. 31, 2012

Dec. 31, 2012

Oct. 31, 2009

Oct. 31, 2012

31-May-12

Sep. 30, 2013

ONSOLIS[Member]

ONSOLIS[Member]

EU [Member]

EU [Member]

US [Member]

Meda License Development and Supply Agreement [Member]

Meda License Development and Supply Agreement [Member]

Milestones [Member]

EU [Member]

EU [Member]

EU [Member]

ONSOLIS[Member]

Revenue Recognition, Multiple-deliverable Arrangements [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Patent expiration year

'

'

'2020

'

'

'

'

'

'

'

'

'

Aggregate milestones and services revenue recognized

$2,072,590

$1,875,446

$5,603,516

$34,677,583

'

'

$17,500,000

'

$59,700,000

$2,500,000

$2,500,000

'

Remaining deferred revenue related to the EU Media arrangement milestones

'

'

'

'

'

'

'

'

'

'

'

1,300,000

Additional revenues in milestones

'

'

'

'

'

'

'

5,000,000

'

'

'

'

Product royalty revenues

924,272

'

1,779,373

'

1,800,000

0

'

'

'

'

'

'

Cost of product royalties

$643,486

$375,000

$1,708,693

$1,125,000

$1,700,000

$1,100,000

'

'

'

'

'

'

Shelf life of the product

'

'

'24 months

'

'

'

'

'

'

'

'

'

Endo_License_and_Development_A1

Endo License and Development Agreement - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended		1 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Jan. 17, 2012	31-May-12
			Milestone				Endo License and Development Agreement [Member]
Revenue Recognition, Milestone Method [Line Items]	'	'	'	'	'	'	'
Non-refundable payment received	'	'	'	'	'	$30,000,000	'
Potential milestone payments	95,000,000	'	95,000,000	'	'	'	'
Number of potential milestone payments	'	'	6	'	'	'	'
Potential milestone payments on intellectual property rights	'	'	35,000,000	'	'	'	'
Potential milestone payments on issuance of patent	15,000,000	'	15,000,000	'	'	'	'
Potential milestone payment receivable clinical development	'	'	20,000,000	'	'	'	'
Potential milestone payment receivable regulatory events	'	'	40,000,000	'	'	'	'
Payment receivable on achievement of potential sales milestones	55,000,000	'	55,000,000	'	'	'	'
Number of potential sales milestones	'	'	4	'	'	'	'
Recognized up-front payment allocated to the license	'	'	15,600,000	'	'	'	'
Recognized up-front payment to clinical trial material and development services	'	'	14,400,000	'	'	'	'
Upfront payment	'	'	0	'	'	'	'
Aggregate milestones and services revenue recognized	2,072,590	1,875,446	5,603,516	34,677,583	'	'	15,000,000
Estimated amount recognized against clinical services deliverable	'	'	5,100,000	'	5,200,000	'	'
Deferred revenue income of the research and development activities	$4,100,000	'	$4,100,000	'	'	'	'
Term of Endo Agreement	'	'	'10 years	'	'	'	'
Extended patent on drug delivery technology	'	'	'2020 to 2027	'	'	'	'

Arcion_License_Agreement_Addit

Arcion License Agreement - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'	'
Common stock locking period	'	'	'9 months	'
Milestone payments increased	'	'	$8,000,000	'
Research and development expense	16,387,194	12,546,912	41,177,577	23,804,276
US [Member]	'	'	'	'
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'	'
Potential Payments upon achieving certain pre-determined sales thresholds in the U.S	'	'	60,000,000	'
US [Member] | Minimum [Member]	'	'	'	'
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'	'
Milestone Sales	'	'	200,000,000	'
Milestone payment receivable from sublicensees	'	'	70,000,000	'
Arcion License Agreement [Member]	'	'	'	'
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'	'
Share issued to Arcion	'	'	500,516	'
Fair market value of unregistered shares issued	'	'	2,100,000	'
Potential payments upon filing and acceptance	'	'	2,500,000	'
Royalty term description	'	'	'The royalty term for any given country is the later of (i) the first date there are no valid claims against any Arcion patent, (ii) expiration of patent exclusivity or (iii) tenth anniversary of the first commercial sale.	'
Research and development expense	'	'	2,100,000	'
Arcion License Agreement [Member] | Minimum [Member]	'	'	'	'
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'	'
Potential milestone payment upon FDA approval	'	'	17,500,000	'
Arcion License Agreement [Member] | Maximum [Member]	'	'	'	'
Research and Development Arrangement, Contract to Perform for Others [Line Items]	'	'	'	'
Potential milestone payment upon FDA approval	'	'	$35,000,000	'

Other_License_Agreements_and_A1

Other License Agreements and Acquired Product Rights - Additional information (Detail) (USD $)	1 Months Ended			9 Months Ended	1 Months Ended
In Millions, unless otherwise specified	Jul. 29, 2013	Nov. 30, 2011	Oct. 07, 2010	Sep. 30, 2013	31-May-10
	TTY License and Supply Agreement [Member]	TTY License and Supply Agreement [Member]	TTY License and Supply Agreement [Member]	TTY License and Supply Agreement [Member]	Kunwha License Agreement [Member]
Other License Agreements And Acquired Product Rights [Line Items]	'	'	'	'	'
Upfront payment	'	'	$0.30	'	$0.30
Up-front payment net of tax	'	'	'	'	0.25
Milestone payments	'	'	1.3	'	1.3
Milestone payments net of tax	'	'	'	'	1.1
Expiration date of the agreement	'	'	'	'	23-Jul-27
Term of the agreement	'	'	'	'15 years	'
Milestone payment received	$0.30	$0.30	'	'	'

MidCap_Secured_Loan_Facility_A

MidCap Secured Loan Facility - Additional Information (Detail) (USD $)	1 Months Ended	9 Months Ended
In Millions, except Share data, unless otherwise specified	Jul. 05, 2013	Sep. 30, 2013
Debt [Line Items]	'	'
Secured loan facility	$20	'
Net proceeds in aggregate amount	19.9	'
Unregistered shares of common stock	'	357,356
Warrant exercise price	'	4.2
Days of volume-weighted average share price	'	'20-day volume-weighted average share price of the Common Stock prior to the closing of the Loan
Warrant exercisable term	'	'5 years
Amortization Period of Discount	'	'3 years
Term of loan	'	'36 months
Interest rate	'	8.45%
LIBOR floor Rate	'	0.50%
Interest rate at period end	'	8.95%
Final payment fee Rate	'	3.50%
Closing fee	'	0.50%
Loan amount prepaid in the first year of the Loan	'	5.00%
Loan amount prepaid in each year thereafter	'	3.00%
Prepayment of principal amount of the Loan rate	'	50.00%
Cash prepayment fee of principal amount of Loan	'	2.00%
Percentage of prepayment amount to purchase shares of Common Stock	'	2.00%
Mid Cap [Member]	'	'
Debt [Line Items]	'	'
Secured loan facility	20	'
Net proceeds in aggregate amount	19.9	'
Unregistered shares of common stock	'	357,356
Warrant exercise price	'	4.2
Notice Period	'	'10 days
Rate of interest Applicable to obligations	'	4.00%
Secured loan facility due to Midcap	'	$20

MidCap_Secured_Loan_Facility_S

MidCap Secured Loan Facility - Schedule Showing Allocation of Secured Loan Facility to Notes Payable and Midcap Warrants (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Debt [Line Items]	'
Total proceeds	$20,000,000
Note Payable [Member]	'
Debt [Line Items]	'
Total proceeds	19,013,648
Midcap Warrant [Member]	'
Debt [Line Items]	'
Total proceeds	$986,352

MidCap_Secured_Loan_Facility_S1

MidCap Secured Loan Facility - Schedule of Fair Value of Warrants (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Market price of stock	$4.41
Term of warrant	'5 years
Volatility	81.05%
Risk free interest rate	2.90%

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	Sep. 30, 2013
Share data in Millions, unless otherwise specified
Related Party Transactions [Abstract]	'
Shares of common stock of Biovest International, Inc.	2
Value of warrants	$0

Stockholders_Equity_Additional

Stockholders' Equity - Additional information (Detail) (USD $)	9 Months Ended			1 Months Ended	6 Months Ended	9 Months Ended		9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Aug. 31, 2013	Jun. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
			Series A Preferred Stock [Member]	Restricted Stock Units (RSUs) [Member]	Restricted Stock Units (RSUs) [Member]	Restricted Stock Units (RSUs) [Member]	Mid Cap [Member]	Directors and Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'	'
Company Issued, RSUs	'	'	'	118,853	'	1,078,336	'	177,110
Fair value of shares granted	'	'	'	'	'	'	'	$0.50
Term of options granted period	'10 years	'	'	'	'	'	'	'
Vesting period of shares	'3 years	'	'	'	'	'	'	'
Weighted average grant date fair value of options granted	$2.97	'	'	'	'	'	'	'
Number of options granted in period with exercise price below market price	0	'	'	'	'	'	'	'
Unrecognized compensation cost related to unvested share-based compensation awards granted	7.4	'	'	'	'	'	'	'
Unrecognized compensation cost related to unvested share-based compensation awards granted year	'2019	'	'	'	'	'	'	'
Purchase of shares	357,356	'	'	'	'	'	357,356	'
Common Stock at a price	4.2	'	'	'	'	'	4.2	'
Warrants fair value	'	'	'	'	'	'	1	'
Fair market value of shares granted	4.5	'	'	'	'	'	'	'
Options vesting Remaining period	'3 years	'	'	'	'	'	'	'
Shares issued ,RSUs	'	'	'	'	3,125	63,853	'	'
fair value of RSU	'	'	'	'	0.01	'	'	'
fair value of RSU	'	'	'	$0.60	'	'	'	'
Company Issued	'	'	'	'	'	55,000	'	'
Preferred Stock, shares authorized	5,000,000	5,000,000	'	'	'	'	'	'
Series A Preferred shares	$0.00	$0.00	'	'	'	'	'	'
Shares of Series A Preferred were outstanding	'	'	2,709,300	'	'	'	'	'

Stockholders_Equity_Weighted_A

Stockholders' Equity - Weighted Average for Key Assumptions Used in Determining Fair Value of Options Granted (Detail)	9 Months Ended
	Sep. 30, 2013
Weighted average expected life in years	'6 years
Dividend yield	'
Minimum [Member]	'
Expected price volatility	78.76%
Risk-free interest rate	0.81%
Maximum [Member]	'
Expected price volatility	81.65%
Risk-free interest rate	1.20%

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Stock Option Activity (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of Shares, Outstanding at beginning of period	4,279,919
Number of Shares, Granted	177,110
Number of Shares, Exercised	-102,827
Number of Shares, Forfeitures	-218,431
Number of Shares, Outstanding at end of period	4,135,771
Weighted Average Exercise Price Per Share, Outstanding at beginning of period	$3.70
Weighted average Exercise Price Per Share, Exercised	$3.38
Weighted Average Exercise Price Per Share, Forfeitures	$2.71
Weighted Average Exercise Price Per Share, Outstanding at end of period	$3.79
Aggregate Intrinsic Value, Outstanding at end of period	$7,590,138
Officers and Directors [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of Shares, Granted	'
Weighted Average Exercise Price Per Share, Granted	'
Others [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Number of Shares, Granted	177,110
Weighted Average Exercise Price Per Share, Granted	$4.38

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Stock Options Outstanding (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number Outstanding	4,135,771
Aggregate Intrinsic Value	$7,590,138
$ 1.00 - 5.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise Prices, minimum	$1
Range of Exercise Prices, maximum	$5
Number Outstanding	3,229,271
Weighted Average Remaining Contractual Life (Years)	'5 years 7 months 17 days
Weighted Average Exercise Price	$3.08
$ 5.01 - 10.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise Prices, minimum	$5.01
Range of Exercise Prices, maximum	$10
Number Outstanding	906,500
Weighted Average Remaining Contractual Life (Years)	'3 years 10 months 28 days
Weighted Average Exercise Price	$6.30

Stockholders_Equity_Summary_of2

Stockholders' Equity - Summary of Stock Options Exercisable (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Number Exercisable	3,564,174
Aggregate Intrinsic Value	$6,475,065
$ 1.00 - 5.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise Prices, minimum	$1
Range of Exercise Prices, maximum	$5
Number Exercisable	2,657,674
Weighted Average Remaining Contractual Life (Years)	'4 years 11 months 9 days
Weighted Average Exercise Price	$3
$ 5.01 - 10.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise Prices, minimum	$5.01
Range of Exercise Prices, maximum	$10
Number Exercisable	906,500
Weighted Average Remaining Contractual Life (Years)	'3 years 10 months 28 days
Weighted Average Exercise Price	$6.30

Stockholders_Equity_Summary_of3

Stockholders' Equity - Summary of Non-Vested Stock Options (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares [Roll Forward]	'
Nonvested at Beginning of period	854,640
Granted	177,110
Vested	-305,872
Forfeited	-154,281
Nonvested at End of period	571,597
Weighted Average Grant Date Fair Value,Nonvested at September 30, 2013	$2.41
Nonvested at September 30, 2013, Aggregate Intrinsic Value	$1,115,073

Stockholders_Equity_Summary_of4

Stockholders' Equity - Summary of Warrants Outstanding to Purchase Common Stock (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013
			$ 0.01 - 5.00 [Member]	$ 0.01 - 5.00 [Member]
				Midcap Warrant [Member]
Warrants, by Exercise Price Range [Line Items]	'	'	'	'
Range of Exercise Prices, minimum	'	'	$0.01	'
Range of Exercise Prices, maximum	'	'	$5	'
Number Outstanding	4,135,771	4,279,919	'	2,366,792
Weighted Average Remaining Contractual Life (Years)	'	'	'	'11 months 19 days
Weighted Average Exercise Price	$3.79	$3.70	'	$3.93
Aggregate Intrinsic Value	$7,590,138	'	'	$3,560,668

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended
	Jun. 30, 2013
	Patents
Commitments And Contingencies Disclosure [Abstract]	'
Number of Patents under infringement Lawsuit, against the entity rejected by USPTO	3